Pricing Log in Create free account
Saturday 17 October 2026 Export CSTL’s income statement to Excel — free account

Castle Biosciences, Inc.

CSTL Healthcare Diagnostics & Research

Castle Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $344.2 million, up 3.66% from fiscal 2024. In the quarter to June 2026, revenue grew 20.1%, EPS fell 143.8%, free cash flow fell 43.3% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.

31.96 1.84 −5.44%
Market cap
$1.0B
P/E
0.0×
Fwd P/E
−15.2×
Dividend yield
—
F-score
3/9
Altman Z
6.70
Beneish M
−3.49
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 18.65
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 9 8 2 1 8 2 2 3 6 9 5 3
Insider Ownership 1.51%

Capital & Financial Ratios $m

Market Cap 1,030.00
Revenue 357.28
Net Income (19.41)
Free Cash Flow (0.45)
Net Debt (256.47)
Current Ratio 6.04 (at or above 1.5: strong)
Debt/Equity 0.02 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (15.20) (negative: loss-making)
P/S ratio 2.72
P/B ratio 2.07
Past 5Y EPS Growth —
This Y EPS Growth (51.54%) (below 0%: weak)
Next Y EPS Growth 27.39% (at or above 15%: strong)
Next Y revenue growth 8.42%
Next 5Y EPS Growth 24.66% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.0×, against a ten-year median of 2.6×; over the ten years it ranged from 0.5× in 2025 to 20.2× in 2021.
P/S against its own 10 years 34.87%
10-year low 10-year high
P/B against its own 10 years 57.22%
10-year low 10-year high
EV/Sales against its own 10 years 41.14%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 243 293 300 267
Receivables 38 51 43 48
Inventory 8 8 10 11
Other — — — —
296 360 361 341
2023 2024 2025 Q'26
Payables 10 7 19 10
ST’ Debt — 0 0 3
Other — — 1 2
48 49 69 57

Compound Annual Growth %

10y 5y 3y
Sales — 40.60% 35.94%
Cash Flow — 45.51% 0.00%
Earnings — 0.00% 0.00%
Book Value — 2.52% 5.66%

Revenue $m

Mar Jun Sep Dec Year
’26 84 104 — — —
’25 88 86 83 87 344
’24 73 87 86 86 332
’23 42 50 61 66 220
’22 27 35 37 38 137
’21 23 23 23 25 94
’20 17 13 15 17 63
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (22) 15 — — —
’25 (6) 21 23 27 64
’24 (7) 24 23 24 65
’23 (25) (4) 5 19 (6)
’22 (21) (9) (5) (6) (42)
’21 (4) (6) (6) (3) (19)
’20 0 14 (3) 0 10
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (35) 7 — — —
’25 (11) 12 8 20 28
’24 (16) 19 17 17 37
’23 (29) (8) 3 15 (19)
’22 (22) (10) (7) (8) (47)
’21 (4) (7) (7) (4) (22)
’20 (1) 12 (5) (1) 5
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.49) (0.07) — — —
’25 (0.90) 0.15 (0.02) (0.08) (0.83)
’24 (0.09) 0.31 0.08 0.32 0.62
’23 (1.10) (0.70) (0.26) (0.10) (2.14)
’22 (0.97) (0.06) (0.77) (0.78) (2.58)
’21 (0.17) (0.35) (0.47) (0.25) (1.24)
’20 0.03 (0.08) (0.23) (0.23) (0.54)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — 15.26 21.01 37.99 15.58 9.26 16.97 14.59

Analyst estimates 2026–2028

Powerpack
High — — — 39.77 78.40 107.69 48.40 29.59 35.84 42.18
People
People Employees — — 96 135 201 345 543 610 761 883
Revenue/emp, $m — 0.00 0.24 0.38 0.31 0.27 0.25 0.36 0.44 0.39
Income, $m
Income, $m Revenue — 14 23 52 63 94 137 220 332 344
Gross margin, % — 63.33 76.75 85.91 84.54 83.18 76.64 79.53 81.87 79.37
EBT — (12) (6) 5 (10) (40) (69) (57) 22 (30)
EBT margin, % — (89.86) (27.90) 10.31 (16.28) (42.53) (50.28) (26.10) 6.49 (8.57)
Net income — 0 (6) 5 (10) (31) (67) (57) 18 (24)
Depreciation — 0 1 2 1 3 9 7 9 37
Per share, $
Per share, $ Revenue — 0.83 11.95 6.04 3.31 3.74 5.26 8.20 11.96 11.88
Earnings — (0.92) (3.34) 0.35 (0.54) (1.24) (2.58) (2.14) 0.66 (0.83)
Cash flow — (0.73) (6.45) 0.82 0.52 (0.76) (1.60) (0.21) 2.34 2.22
Capex — 0.00 (0.15) (0.11) (0.25) (0.14) (0.21) (0.51) (1.02) (1.24)
Free cash flow — (0.73) (6.60) 0.71 0.27 (0.89) (1.81) (0.72) 1.32 0.98
Book value — (0.95) (29.68) 9.92 21.96 16.38 15.32 14.60 16.41 16.24
Shares, m — 17 2 9 19 25 26 27 28 29
Valuation, ×
Valuation, × P/E — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 41.00 0.00
P/S — 1.70 1.70 5.69 20.29 11.45 4.33 2.68 2.23 3.28
P/B — 0.00 0.00 3.47 3.06 2.62 1.49 1.50 1.62 2.39
EV/Sales — 1.96 1.96 4.27 14.11 8.04 2.54 1.64 1.38 2.44
EV/FCF — (13.90) (13.90) 36.41 172.70 (33.67) (7.39) (18.72) 12.51 29.55
Cash, $m
Cash, $m Operating cash flow — (12) (12) 7 10 (19) (42) (6) 65 64
Capex — 0 0 (1) (5) (3) (5) (14) (28) (36)
Free cash flow — (12) (13) 6 5 (22) (47) (19) 37 28
Balance, $m
Balance, $m Working capital — 1 11 101 409 329 256 248 311 292
Total debt — 20 25 25 — 8 13 — 10 10
Net debt — 19 20 (74) (410) (322) (245) (243) (283) (289)
Shareholders’ equity — (16) (57) 85 416 412 399 391 456 471
Returns, %
Returns, % ROA — (95.00) (90.72) 4.21 (3.68) (6.94) (14.76) (12.76) 3.71 (4.35)
ROIC — 0.00 0.00 40.21 (70.02) (27.78) (29.60) (28.67) 3.13 (14.72)
ROE — 28.65 19.02 20.95 (4.11) (7.56) (16.56) (14.54) 4.31 (5.21)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Castle Biosciences, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
VCYT Veracyte, Inc. $3.6B 29.9× 45.1× +15.49% (above 0%: growing) n/m +32.95% (above 0%: growing) 72.21% 15.29% Compare
CDNA CareDx, Inc. $3.5B 29.7× 2,967× +52.23% (above 0%: growing) n/m +223.42% (above 0%: growing) 73.50% 85.81% Compare
NEO NeoGenomics, Inc. $2.2B — (loss-making) — (loss-making) +11.21% (above 0%: growing) n/m −16.18% (below 0%: shrinking) 45.56% (4.85%) Compare
WGS GeneDx Holdings Corp. $2.1B — (loss-making) — (loss-making) +11.44% (above 0%: growing) n/m −585.59% (below 0%: shrinking) 68.37% (15.25%) Compare
PSNL Personalis, Inc. $1.7B — (loss-making) — (loss-making) +29.96% (above 0%: growing) n/m −123.46% (below 0%: shrinking) 21.21% (150.25%) Compare
OPK OPKO Health, Inc. $1.2B — (loss-making) — (loss-making) +4.32% (above 0%: growing) n/m +46.46% (above 0%: growing) 48.92% (4.26%) Compare
CSTL Castle Biosciences, Inc. $1.0B — (loss-making) — (loss-making) +20.14% (above 0%: growing) n/m −43.33% (below 0%: shrinking) 77.11% (2.96%)
FLGT Fulgent Genetics, Inc. $587.2M — (loss-making) — (loss-making) +4.38% (above 0%: growing) n/m +25.36% (above 0%: growing) 30.07% (42.25%) Compare
MYGN Myriad Genetics, Inc. $416.1M — (loss-making) — (loss-making) −10.51% (below 0%: shrinking) n/m +43.90% (above 0%: growing) 66.60% (20.40%) Compare
Median of peers $1.9B — — +11.33% — +29.16% 57.76% (10.05%)

All 52 Diagnostics & Research stocks →

Castle Biosciences, Inc. (CSTL) key facts

  • Strength: Castle Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $344.2 million, up 3.66% from fiscal 2024.
  • Castle Biosciences, Inc. (CSTL) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, CSTL traded at $31.96, a market capitalization of $1.0 billion.
  • Return on equity was −5.21% and debt-to-equity 0.02.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 6.70 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Castle Biosciences, Inc. (CSTL) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/CSTL · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com